Icosavax Begins Phase 2 Trial Of IVX-A12 Against RSV And hMPV In Older Adults
Portfolio Pulse from Benzinga Newsdesk
Icosavax has initiated a Phase 2 trial for its IVX-A12 vaccine candidate against RSV and hMPV in older adults. The company previously reported positive interim Phase 1 results in May 2023.
June 20, 2023 | 12:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Icosavax's Phase 2 trial initiation for IVX-A12 may positively impact its stock price as it progresses in the development of the vaccine candidate.
The initiation of the Phase 2 trial for IVX-A12 demonstrates progress in the development of the vaccine candidate. This news may be seen as a positive milestone for Icosavax, potentially leading to an increase in its stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100